Navigation Links
Goodwin Biotechnology Announces a Collaboration with Spectros Corporation
Date:10/24/2011

PLANTATION, Fla. and PORTOLA VALLEY, Calif., Oct. 24, 2011 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) and Spectros Corporation jointly announced a collaboration for the process development and cGMP manufacturing of an antibody: dye conjugate that will be used in Phase I and Phase II clinical trials.

"The leading surgical treatment for prostate cancer is prostatectomy, or removal of the prostate," noted David Benaron, CEO at Spectros Corporation. "Unfortunately, residual tumor remains at the edge of surgery about 30% of the time, leading to a significantly higher risk of local recurrence of the cancer and higher rates of death. By collaborating with GBI on the conjugation of a fluorescent dye and a monoclonal antibody that has a high level of affinity with the prostate-specific membrane antigen, we aim to identify and minimize the residual tumor, thereby reducing the number of people who have to receive additional treatment such as high doses of radiation. This type of cancer detection, called Molecular Imaging, may represent an important advance in cancer by improving the diagnosis, individualized treatment selection and monitoring, and even survival. We look forward to clinical trials with this agent, ProstaFluor®, beginning next year."

"We're excited about the opportunity to contribute a decade of bioconjugation experience to this important project," said Muctarr Sesay, PhD, Vice President of Process Development at GBI. "The potential of this innovative approach may represent a new paradigm in the way patients are diagnosed and treated, and contribute significantly to the quality of life of those affected by this insidious disease."

About Goodwin Biotechnology, Inc.Goodwin Biotechnology is a fully integrated cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines. GBI has the expertise and experience in cell line development, process development and GMP manufacturing of recombinant proteins and antibodies, as well as conjugated therapeutic proteins (e.g., antibodies conjugated to linkers for radioimmune therapy and diagnostics, other antibodies, proteins, chemotoxins, or plant toxins) by leveraging our proprietary conjugation technology. By working with GBI, our clients can enhance the value of their product candidates with clear development and manufacturing strategies and a road map to meet product requirements from the milligram, gram and kilogram range as the product candidates move along the clinical approval pathway. With nearly 20 years of experience as an independent contract manufacturer, GBI has worked with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established biopharmaceutical companies.

About Spectros CorporationSpectros Corporation makes advanced molecular sensing and imaging devices which shed light on life-threatening diseases, including ischemia and cancer. The company's champion product, the T-Stat® broadband Tissue Oximeter, was the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue. Spectros also develops molecular diagnostic tools for breast and prostate cancer, including the ProstaFluor® contrast agent described herein. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.For more information, please contact:Goodwin Biotechnology:Spectros Corporation:Dave Cunningham

Ms. Elizabeth van Thillo-RohlffDirector of Business Development

Director, Marketing and SalesPhone: (954) 327-9639

Phone: 650-529-2865Email: DCunningham@GoodwinBio.com

Email: info@spectros.com
'/>"/>

SOURCE Goodwin Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics
2. Goodwin Biotechnology Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
3. HUYA Bioscience International and Tianjin International Joint Academy of Biotechnology and Medicine Form Alliance
4. The Patent Board, IP Tracking and Analysis Firm, Ranks Heskas Science Strength in Biotechnology Industry Top 50
5. Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger
6. Top 450 Biotechnology (Pharmaceuticals) Report (Global)
7. STELARA® Awarded 2011 Prix Galien USA in Best Biotechnology Product Category
8. 2011 Prix Galien USA Final Candidates Announced: Competing for Best Biotechnology Product and Best Pharmaceutical Agent
9. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
10. Generex Biotechnology Corporation CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
11. Generex Biotechnology Corporation CEO to Present Live, Online at RetailInvestorConferences.com on May 5th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)...  A recent study at Shriners Hospitals for Children ... the country dedicated to the treatment of pediatric burns ... the Surfacide Helios ® UV-C Disinfection System is ... pathogens not killed by the EVS (manual) cleaning process ... Burn Association,s 49th Annual Meeting in Boston ...
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immunotherapy successfully passed early toxicology and efficacy studies. The ... to target a specific protein, MAGE A, in an ... breast cancer. After 4 weeks of ... to show very little toxicity in a full toxicology ...
(Date:3/27/2017)... March 27, 2017  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ... to offer shares of common stock in an underwritten ... file with the Securities and Exchange Commission (the "SEC"). ... and there can be no assurance as to whether ... to the actual size or terms of the offering. ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may ... of groin injury, it occurs when the muscles around the pelvis become inflamed. ... around the lower torso, as well as accompanying tenderness and weakness. Without proper ...
(Date:3/27/2017)... Georgia (PRWEB) , ... March 27, 2017 , ... ... to announce that for a second year in a row; they are the ... healthcare designers in the industry voted on the award at Design Connections 2017. ...
(Date:3/27/2017)... ... ... The Anaheim Hills office accelerates and supports FNCC’s growth and further strengthens ... professionals over the past 6 months and is continuing to recruit new talent with ... of 2017. , “This new office is a direct result of our strong ...
(Date:3/27/2017)... ... March 27, 2017 , ... Golden Triangle Emergency Center will ... April 3rd to commemorate the two-year anniversary of the facility. The event will ... two great years while also familiarizing themselves with the facility. , In the ...
(Date:3/26/2017)... (PRWEB) , ... March 26, 2017 , ... ... worldwide to receive the RealSelf 100 Award, a prestigious award honoring the top ... procedures and to find and connect with doctors and clinics. , In 2016, ...
Breaking Medicine News(10 mins):